Last reviewed · How we verify
Gene Therapy product:vMCO-I — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Gene Therapy product:vMCO-I (Gene Therapy product:vMCO-I) — Nanoscope Therapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gene Therapy product:vMCO-I TARGET | Gene Therapy product:vMCO-I | Nanoscope Therapeutics Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gene Therapy product:vMCO-I CI watch — RSS
- Gene Therapy product:vMCO-I CI watch — Atom
- Gene Therapy product:vMCO-I CI watch — JSON
- Gene Therapy product:vMCO-I alone — RSS
Cite this brief
Drug Landscape (2026). Gene Therapy product:vMCO-I — Competitive Intelligence Brief. https://druglandscape.com/ci/gene-therapy-product-vmco-i. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab